Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.

You may also be interested in...



Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion

Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.

Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion

Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.

Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.

Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel